Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / TNFAIP6

TNFAIP6

Basics

Aliases:
This biomarker is also known as:
  • tumor necrosis factor, alpha-induced protein 6,
  • tumor necrosis factor-inducible gene 6 protein,
  • Tumor necrosis factor-inducible gene 6 protein,
  • P98066,
  • TSG-6,
  • Hyaluronate-binding protein,
  • TNF alpha-induced protein 6,
  • tumor necrosis factor-stimulated gene-6 protein,
  • TSG6,
  • TNF-stimulated gene 6 protein,

View in BioMuta

Description…

TNFAIP6 is a secretory protein that contains a hyaluronan-binding domain, and thus is a member of the hyaluronan-binding protein family. It is possibly involved in cell-cell and cell-matrix interactions during inflammation and tumorigenesis. Enhanced levels of this protein are found in the synovial fluid of patients with osteoarthritis and rheumatoid arthritis.

Attributes

QA State: Curated
Type: Protein
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Two
QA State: Under Review

Overview

TNFAIP6 (TSG6) localized to vascular-like structures in ovarian cancer but not in normal ovaries.

Performance Comment

TNFAIP6 (TSG6) was one of 13 genes out of 50 selected for further validation in PMID:21617380. Average expression of TNFAIP6 was significantly higher in epithelial ovarian cancer tumors than any other normal tissue tested.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.

Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html